← Eichor
Study identifier: NCT06076005 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor

Condition: Lung Cancer Stage IV  ·  Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The distribution of demographic, clinical, radiological, pathological and molecular characteristics of lung cancer at the time of diagnosis, as well as preferential association between elements of those domains, have not been specifically studied in Italy. The aim of the present project is to assess, in a systematic fashion, the demographic, clinical, radiological, pathological and molecular characteristics of advanced lung cancer at the time of diagnosis in a large Italian cohort of consecutive patients referred to two tertiary referral centers.

This description comes directly from the study's public registry record.

Talk to the study team

Rocco Trisolini, MD  ·  0630154163  ·  rocco.trisolini@policlinicogemelli.it

Always discuss trial participation with your own doctor first.

Locations (3)

Interventional Pulmonology Division - Fondazione Policlinico Universitario A. Gemelli IRCCSRoma, ItalyRecruiting
Istituto Nazionale Tumori Regina ElenaRoma, ItalyNot Yet Recruiting
Medical Oncology Division - Fondazione Policlinico Universitario Agostino Gemelli IRCCSRoma, ItalyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06076005